Treatment of Essential Thrombocythemia
All patients with essential thrombocythemia should be risk-stratified first, then treated with low-dose aspirin for very low and low-risk disease, while high-risk patients (age >60 years with JAK2 mutation OR prior thrombosis) require cytoreductive therapy with hydroxyurea as first-line agent, with pegylated interferon-α as an alternative. 1, 2, 3
Risk Stratification Framework
The treatment algorithm hinges on categorizing patients into four risk groups 3:
- Very low risk: Age ≤60 years, no thrombosis history, JAK2 wild-type
- Low risk: Age ≤60 years, no thrombosis history, JAK2 mutation present
- Intermediate risk: Age >60 years, no thrombosis history, JAK2 mutation present
- High risk: Prior thrombosis OR (age >60 years with JAK2 mutation)
This stratification directly determines therapeutic intensity, as the primary treatment goal is preventing thrombotic complications that drive morbidity and mortality 2, 3.
Treatment by Risk Category
Very Low and Low Risk Disease
Low-dose aspirin once daily is the standard approach 3. For patients with microvascular symptoms (headaches, lightheadedness, acral paresthesias, erythromelalgia), consider twice-daily aspirin 3. Observation alone without aspirin may be considered only in very select cases, but aspirin is generally preferred given the thrombotic risk 2, 4.
Intermediate Risk Disease
Cytoreductive therapy is optional but should be strongly considered, particularly if additional risk factors are present (extreme thrombocytosis, cardiovascular risk factors) 3. The decision requires weighing individual patient factors, but err toward treatment if any concerning features exist.
High Risk Disease
Cytoreductive therapy is mandatory 2, 3. The target platelet count in daily practice is <400 × 10⁹/L, though some guidelines suggest <600 × 10⁹/L as acceptable 2.
Cytoreductive Therapy Selection
First-Line Options
Hydroxyurea is the first-line cytoreductive agent 1, 2, 5, 3. Dosing typically starts at 15-20 mg/kg/day and is adjusted to achieve platelet control. The typical maintenance dose is 2 g/day (2.5 g/day for patients >80 kg body weight) 2.
Pegylated interferon-α is an equally valid first-line alternative, particularly for younger patients concerned about long-term leukemogenic risk, though the PROUD-PV trial showed non-inferior efficacy with higher tolerability 1, 3. A phase III trial comparing hydroxyurea to pegylated interferon is ongoing, but both are considered appropriate first-line choices 6.
Defining Hydroxyurea Resistance/Intolerance
Switch to second-line therapy if any of the following occur after 3 months of ≥2 g/day hydroxyurea (≥2.5 g/day if >80 kg) 2:
- Platelet count remains ≥600 × 10⁹/L
- Platelet count <400 × 10⁹/L with white blood cells <2,500/μL
- Platelet count <400 × 10⁹/L with hemoglobin <10 g/dL
- Leg ulcers or unacceptable mucocutaneous manifestations
- Hydroxyurea-related fever
Second-Line Options
Anagrelide is the preferred second-line agent for patients with hydroxyurea resistance or intolerance 2, 6, 4, 3.
Busulfan is another second-line option 3.
Ruxolitinib is NOT superior to current second-line treatments for essential thrombocythemia, as demonstrated by the MAJIC trial 1. It should be reserved for clinical trial settings or post-ET myelofibrosis.
Critical Caveats
Extreme Thrombocytosis (>1,500 × 10⁹/L)
These patients have increased hemorrhagic risk due to acquired von Willebrand syndrome 4, 3. Avoid aspirin until platelet count is reduced with cytoreductive therapy to prevent paradoxical bleeding.
Cardiovascular Risk Factor Management
Aggressively control all modifiable cardiovascular risk factors (hypertension, diabetes, hyperlipidemia, smoking) as these compound thrombotic risk independent of platelet count 5, 4.
Pregnancy Management
This requires specialized protocols beyond routine management. Aspirin and interferon-α are generally safe; hydroxyurea and anagrelide are contraindicated 7, 3.
What Treatment Does NOT Accomplish
No current therapy has been proven to prevent progression to myelofibrosis or acute leukemia, or to improve overall survival 5. Treatment is purely aimed at preventing thrombohemorrhagic complications and controlling symptoms. This is a critical counseling point for patients.
Monitoring
Patients on observation or aspirin alone should be seen every 3-6 months. Those on cytoreductive therapy require more frequent monitoring initially (every 4-6 weeks) until stable, then every 3 months 2. Serial bone marrow biopsies or mutation burden assessments are not recommended outside clinical trials 2.